CTSO - Cytosorbents Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.6800
+0.0700 (+1.52%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.6100
Open4.6000
Bid4.7000 x 800
Ask4.6900 x 1300
Day's Range4.4500 - 4.7300
52 Week Range3.4900 - 8.6100
Volume201,824
Avg. Volume184,174
Market Cap151.743M
Beta (5Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-0.6460
Earnings DateMar 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.90
  • PR Newswire

    CytoSorb Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin

    CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, highlights the recent publication entitled, "Hemoadsorption Improves Survival of Rats Exposed to an Acutely Lethal Dose of Aflatoxin B1" in the journal, Scientific Reports, a Nature Research publication.

  • PR Newswire

    CytoSorbents Reports Preliminary 2019 Financial Results and Issues Stockholder Letter

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, issues a stockholder letter from Dr. Phillip Chan, Chief Executive Officer of CytoSorbents, and pre-announces preliminary unaudited fourth quarter 2019 and full-year 2019 results ahead of filing its Form 10-K.

  • 2 Healthcare Stocks Set to Rally into the New Year
    TipRanks

    2 Healthcare Stocks Set to Rally into the New Year

    The psychology of investing presents an interesting conundrum. When a stock soars, the natural tendency is to want to get in on the action, as the FOMO kicks in and the allure of further gains is hard to resist. This is often the wrong choice as the stock will likely be sold off at a premium to latecomers.Conversely, a beaten-down stock induces tremors of fear. The inevitable concern about the stock’s low valuation and negative market sentiment can cause potential investors to avoid backing what appears to be a losing horse. This is sometimes the case, but other times share price weakness represents the best time to get in before a stock sets off on its upward trajectory.So how can you tell the losers from the winners? While nothing is certain, the experts on Wall Street can lend a helping hand. In a recent note to clients, B. Riley FBR analyst Andrew D’Silva highlights stocks in the healthcare sector which he thinks are set to make headway in 2020.“Each company either exited 2019 on a strong footing, where momentum is poised to carry over into 2020, or has fallen out of favor, but execution will result in a reversal,” the analyst commented.Using TipRanks’ Stock Comparison tool, we were able to zoom in on 2 of D’Silva’s choices. Whether beaten-down or flying high, all have plenty of room for upside, and all currently have a Strong Buy consensus rating from the Street. Let's take a closer look:Alimera Sciences (ALIM)Alimera Sciences had a miserable 2019. The retinal disease focused company lost 30% of its share price over the year. So far, 2020 has not been kinder, either. The share price is down by almost 10% year-to-date.So, should investors stay away? Absolutely not, says D’Silva. Now is the time to reassess the biopharma’s potential.The drop, he says, was instigated by the significant impact of 2Q19 results missing expectations, which were mostly attributed to a significant loss of domestic sales force. During 1H19, “several companies launched ophthalmic offerings and established/expanded their sales teams.” The numerous employment opportunities contributed to a depletion of Alimera’s own sales team.“We believe this compounded investor working capital concerns, as ALIM's $40 million term loan's interest-only period was scheduled to end within a year's time,” D’Silva noted.However, the analyst expects a “significant reversal this year.” He cited a resolution to the company’s sales force turnover issues, an expanding international footprint, and the “significant milestone” of management’s positive 2020 adjusted EBITDA guidance as reasons for the anticipated turnaround. Furthermore, a new debt refinancing arrangement “cleared a significant working capital overhang.”D’Silva noted, “While we expected that the company would refinance its term loan, we believe this should remove a significant trading overhang related to investor fears that ALIM would need to raise capital through a highly dilutive equity financing to fund operations and meet its debt obligation.”D'Silva, therefore, reiterated a Buy rating on Alimera along with a price target of $24. With ALIM currently trading at $6.91, the upside potential comes in at a massive 243%. (To watch D’Silva’s track record, click here)All in all, three analysts are currently keeping track of the eye disease specialist and all three see better days ahead too, rating the stock a Buy. With an average price target of $20.50, the figure suggests potential upside of nearly 200%. (See Alimera price targets and analyst ratings on TipRanks)CytoSorbents Corporation (CTSO)In a similar vein to Alimera, CytoSorbents is a beaten-down stock, displaying even further wreckage. It lost 52% of its share price during last year’s bull run.CTSO’s blood purification technologies are used to control deadly inflammation in critically-ill and cardiac surgery patients. After exhibiting revenue growth of 51% in 2018, the growth curve slowed down to 9% year-over-year in the first three quarters of 2019.D’Silva explained, “While the slower top-line growth could be concerning at first glance, the two primary reasons for the slowdown were related to two CS distributors and Fresenius Medical Care—which, together, accounted for ~15%-20% of the CTSO top line in 2018—entering 2019 with excess inventory, as well as CTSO running into sales-force bandwidth issues in its largest market, Germany.”With CTSO commencing sales in Poland, Sweden, Denmark, Norway, and the Netherlands, D’Silva foresees a turnaround in the months ahead.“While we don't anticipate CTSO realized significant benefits from new direct sales regions in 4Q19, as most new sales hires were onboarded in 2H19, we do expect CTSO's expanded footprint to provide a significant benefit this year… Meanwhile, We believe there are numerous clinical and regulatory catalysts are on the horizon that should be significant value drivers for the stock if successful,” said the analyst.As a result, D’Silva kept his Buy rating and supports it with an ambitious $12 price target. Attaining this number will provide a very healthy 210% gain in the next twelve months.Does the Street agree? Those who are taking notice certainly do. 3 Buy ratings and no Holds or Sells add up to a unanimous Strong Buy consensus rating. The recommendation comes alongside an average price target of $11 and implies upside potential of 176%. (See CytoSorbents stock-price forecast and analyst ratings)

  • PR Newswire

    CytoSorbents to Present at Biotech Showcase™ 2020

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at Biotech Showcase™ 2020 on Monday, January 13, 2020 in San Francisco, CA and meet with investors in 1x1 meetings throughout the day.

  • Is Cytosorbents Corporation (CTSO) A Good Stock To Buy?
    Insider Monkey

    Is Cytosorbents Corporation (CTSO) A Good Stock To Buy?

    Investing in small cap stocks has historically been a way to outperform the market, as small cap companies typically grow faster on average than the blue chips. That outperformance comes with a price, however, as there are occasional periods of higher volatility. The last 12 months is one of those periods, as the Russell 2000 […]

  • Trade Alert: The CEO, President & Director Of Cytosorbents Corporation (NASDAQ:CTSO), Phillip Chan, Has Just Spent US$59k Buying Shares
    Simply Wall St.

    Trade Alert: The CEO, President & Director Of Cytosorbents Corporation (NASDAQ:CTSO), Phillip Chan, Has Just Spent US$59k Buying Shares

    Whilst it may not be a huge deal, we thought it was good to see that the Cytosorbents Corporation (NASDAQ:CTSO) CEO...

  • PR Newswire

    CytoSorbents to Present at the Piper Jaffray 31st Annual Healthcare Conference

    CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Piper Jaffray 31st Annual Healthcare Conference on Thursday, December 5, 2019 in New York, NY, and meet with investors in 1x1 meetings throughout the day.

  • PR Newswire

    CytoSorbents Changes Contract Research Organizations and Temporarily Pauses Enrollment in REFRESH 2-AKI Study

    CytoSorbents Corporation (NASDAQ: CTSO) is temporarily pausing enrollment of its REFRESH 2-AKI study at the recommendation of its Data Monitoring Committee (DMC) as the Company transitions to a new contract research organization (CRO) for the trial. The DMC recommended this pause following a blinded, interim, milestone review of clinical study data. The DMC requested that additional data analysis and clinical data, not pre-specified in the current version of the protocol, be provided by CytoSorbents and its newly appointed CRO, to improve the monitoring of patient safety endpoints. There were no specific adverse events of clinical outcomes cited in the DMC's initial recommendations following this review. To enable the efficient and thorough collection of this information for patients that have completed the trial, the DMC has recommended a pause in enrollment. CytoSorbents and its CRO plan to fulfill the requests of the DMC, which may require the filing of a protocol amendment with the FDA, in a timely manner.

  • PR Newswire

    CytoSorbents to Present at the Three Part Advisors 2019 Southwest IDEAS Investor Conference

    MONMOUTH JUNCTION, N.J. , Nov. 19, 2019 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb®  blood purification technology to treat ...

  • PR Newswire

    Dr. Eric Mortensen to Leave CytoSorbents At Year End

    MONMOUTH JUNCTION, N.J., Nov. 6, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that Dr. Eric Mortensen, Chief Medical Officer of CytoSorbents, will leave the company at the end of the year, upon the completion of his current employment contract. Dr. Phillip Chan, MD, PhD, Chief Executive Officer of CytoSorbents stated, "Since joining the company two and a half years ago, Eric has leveraged his extensive industry expertise in clinical trials, medical affairs, and reimbursement to make numerous contributions to the company.

  • PR Newswire

    CytoSorbents Reports Third Quarter 2019 Financial Results

    MONMOUTH JUNCTION, N.J. , Nov. 5, 2019 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly ...

  • Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
    Simply Wall St.

    Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • PR Newswire

    CytoSorbents Announces Additions to its International Clinical Team

    MONMOUTH JUNCTION, N.J. , Nov. 4, 2019 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its  CytoSorb®  blood purification technology to treat ...

  • PR Newswire

    CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom

    MONMOUTH JUNCTION, N.J., Nov. 1, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a leader in blood purification therapies to treat life-threatening conditions, announced the first patient enrollment in the company-sponsored Ticagrelor CytoSorb® Hemoadsorption (TISORB) study in the United Kingdom (U.K.). The Company also announced establishment of a new U.K. operating subsidiary, CytoSorbents UK Limited, that enables it, among other things, to be eligible for certain research tax credits that are expected to subsidize the trial by up to a third of the cost, subject to certain restrictions.

  • PR Newswire

    CytoSorbents to Report Q3 2019 Operating and Financial Results

    MONMOUTH JUNCTION, N.J. , Oct. 30, 2019 /PRNewswire/ --  CytoSorbents Corporation  (CTSO), a critical care immunotherapy leader commercializing its  CytoSorb®  blood purification technology to treat deadly ...

  • PR Newswire

    CytoSorbents Awarded Approximately $3.0 Million by the U.S. Air Force to Advance Development of the K+ontrol System to Treat Severe Hyperkalemia

    MONMOUTH JUNCTION, N.J., Oct. 22, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the U.S. Air Force Materiel Command has awarded the Company a two-year contract valued at up to $2,959,747 as part of the Rapid Innovation Fund (RIF) to advance its program, entitled "K+ontrol Renal Support System for Reduction of Hyperkalemia," towards a U.S. clinical trial designed to support U.S. FDA regulatory approval. Severe hyperkalemia, or dangerously high potassium levels in the blood, is a serious complication of trauma, crush injury, and prolonged limb ischemia.  It is particularly relevant in military trauma, afflicting approximately 6% of U.S. combat casualties in the wars in Iraq and Afghanistan.

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference Lineup for October 15 and 16, 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...

  • Is Cytosorbents Corporation's (NASDAQ:CTSO) CEO Salary Justified?
    Simply Wall St.

    Is Cytosorbents Corporation's (NASDAQ:CTSO) CEO Salary Justified?

    Phillip Chan has been the CEO of Cytosorbents Corporation (NASDAQ:CTSO) since 2009. First, this article will compare...

  • PR Newswire

    CytoSorbents to Present at The MicroCap Rodeo Investor Conference

    MONMOUTH JUNCTION, N.J. , Oct. 10, 2019 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb ® blood purification technology to treat ...

  • PR Newswire

    CytoSorb® Removal of Ticagrelor Intraoperatively Results in Projected Cost Savings of Approximately $5,000 in Each Patient Undergoing Emergency Cardiac Surgery

    MONMOUTH JUNCTION, N.J. , Oct. 4, 2019 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a leader in hemoadsorption therapies to treat life-threatening conditions, announced that Dr. Eric Mortensen ...

  • PR Newswire

    CytoSorbents Announces Positive Surgical Outcomes From CytoSorb Removal Of Antithrombotics In Emergency Cardiothoracic Surgery

    MONMOUTH JUNCTION, N.J. , Oct. 2, 2019 /PRNewswire/ --  CytoSorbents Corporation (NASDAQ: CTSO), a leader using its  CytoSorb®  blood purification technology to treat life-threatening medical and surgical ...

  • PR Newswire

    CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock

    MONMOUTH JUNCTION, N.J., Sept. 25, 2019 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights a new publication entitled, "Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study," in the journal Critical Care. In this study, clinical researchers at Maasstad Hospital and at Erasmus University Medical Center in Rotterdam, Netherlands conducted a retrospective evaluation of 116 patients with septic shock, who required vasopressors to increase their blood pressure, and renal replacement therapy (RRT) due to kidney failure.  Of these, 49 patients received standard of care therapy, and 67 were treated with standard of care plus CytoSorb.

  • Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO)
    Simply Wall St.

    Analysts Expect Breakeven For Cytosorbents Corporation (NASDAQ:CTSO)

    Cytosorbents Corporation's (NASDAQ:CTSO): Cytosorbents Corporation, a critical care focused immunotherapy company...

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin Texas

    Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...

  • PR Newswire

    First Study to Evaluate CytoSorb in Cytokine Release Syndrome (CRS) Following CAR T-cell Immunotherapy to Commence

    MONMOUTH JUNCTION, N.J. , Sept. 16, 2019 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb ®  blood purification technology to ...